Poll: Vote on the Top Breast Cancer, Hematology Abstracts to Watch at ESMO 2025

The 2025 ESMO Congress in Berlin is just around the corner, and anticipation is high for the scientific sessions that will drive discussions and shape care across tumor types. Each year, late-breaking abstracts (LBAs) and evolving thematic tracks highlight the newest strategies for delivering precision, durability, and equity in cancer treatment.

To tap into the perspectives of clinicians across settings, we are launching a new round of community polls focused on the key abstracts, data, and topics in the breast cancer and hematologic oncology spaces that will be shared during this year’s ESMO Congress.

We invite medical, academic, and community oncologists to vote in four short polls—2 for breast cancer and 2 for hematology. Voting is open now on X and LinkedIn through Thursday, October 2.

What Are the Top Abstracts to Watch in Breast Cancer at the 2025 ESMO Congress?

Breast cancer remains a cornerstone of the ESMO program, with pivotal trials addressing novel agents, treatment sequencing, and the role of immunotherapy and targeted approaches across disease stages.

Poll 1: Which breast cancer abstract are you most anticipating at ESMO 2025?

Vote Now: X | LinkedIn

• 291O - DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC)
• LBA20 - Primary results from ASCENT-03: A randomized phase 3 study of sacituzumab govitecan (SG) vs chemotherapy (Chemo) in patients (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are unable to receive PD-(L)1 inhibitors (PD-[L]1i)
• LBA17 - Gedatolisib (geda) + fulvestrant ± palbociclib (palbo) vs fulvestrant in patients (pts) with HR+/ HER2-/PIK3CA wild-type (WT) advanced breast cancer (ABC): First results from VIKTORIA-1
• LBA13 - monarchE: Primary overall survival (OS) results of adjuvant abemaciclib + endocrine therapy (ET) for HR+, HER2-, high-risk early breast cancer (EBC)

Poll 2: Which breast cancer topics are generating the most buzz ahead of ESMO 2025?

Vote Now: X | LinkedIn

• Antibody-Drug Conjugates
• CDK4/6 Inhibitor Approaches
• Targeted Therapy
• Early-Stage Management

What Are the Top Abstracts to Watch in Hematologic Oncology at the 2025 ESMO Congress?

Hematologic malignancies continue to showcase some of the most dynamic advances in oncology, with ESMO providing a platform for practice-shaping updates in lymphomas, leukemias, and myeloma.

Poll 3: Which hematology abstract are you most anticipating at ESMO 2025?

Vote Now: X | LinkedIn

• 1240O - CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory Large B-cell Lymphoma: a Prospective, Single-arm, Single-center, Phase 2 Clinical Trial
• 1241O - Anti-PD-1-Antibody (Tislelizumab) Combined with Chidamide, Lenalidomide and Etoposide for the treatment of refractory/relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single -Arm, Phase II Trial
• 1242O - Sustained marrow and imaging MRD negativity can lead to lenalidomide discontinuation following ASCT in multiple myeloma: Updated results from a prospective cohort study
• 1245MO - Combination of Mitoxantrone Hydrochloride Liposome with Chidamide in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma: Updated Results of the Phase II Study

Poll 4: What hematologic malignancies are you most interested in learning more about during ESMO 2025?

Vote Now: X | LinkedIn

• Non-Hodgkin Lymphoma
• Multiple Myeloma
• MPNs
• T-Cell Lymphoma

Join the Conversation

These four polls are designed to give the oncology community a voice in highlighting the most relevant and practice-shaping updates in breast cancer and hematologic oncology ahead of ESMO 2025. By voting, you’ll help reflect the priorities of clinicians across academic centers, community hospitals, and private practice settings.

The polls are now live on X and LinkedIn, and voting will remain open until Thursday, October 2. Join the discussion, share with colleagues, and check back at the end of the week to see which abstracts and themes your peers are most excited about.